Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on Sarepta Therapeutics with a $174 price target as part of her "New Year’s Countdown" of 10 stocks with 2023 catalysts that should be on investors’ radar. In the coming year, she expects that most investor focus will be on regulatory decisions behind Sarepta’s AAVrh74-based gene therapy encoding micro-dystrophin, SRP-9001, which has a regulatory action date of May 29, Kluska tells investors. It is her expectation that "many patients are likely to utilize this treatment" if approved, the analyst added.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SRPT:
- Sarepta price target raised to $160 from $125 at BTIG
- Sarepta upgraded to Buy at UBS ahead of ‘highly likely’ SRP-9001 approval
- Sarepta upgraded to Buy from Neutral at UBS
- Sarepta price target raised to $174 from $150 at Cantor Fitzgerald
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)